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Abstract
An automated dried blood spot (DBS) elution coupled with solid phase extraction and tandem 
mass spectrometric analysis for multiple fentanyl analogs was developed and assessed. This 
method confirms human exposures to fentanyl, sufentanil, carfentanil, alfentanil, lofentanil, α-
methyl fentanyl, and 3-methyl fentanyl in blood with minimal sample volume and reduced 
shipping and storage costs. Seven fentanyl analogs were detected and quantitated from DBS made 
from venous blood. The calibration curve in matrix was linear in the concentration range of 1.0 
ng/mL to 100 ng/mL with a correlation coefficient greater than 0.98 for all compounds. The limit 
of detection varied from 0.15 ng/mL to 0.66 ng/mL depending on target analyte. Analysis of the 
entire DBS minimized the effects of hematocrit on quantitation. All quality control materials 
evaluated resulted in <15% error; analytes with isotopically labeled internal standards had <15% 
RSD, while analytes without matching standards had 15–24% RSD. This method provides an 
automated means to detect seven fentanyl analogs, and quantitate four fentanyl analogs with the 
benefits of DBS at levels anticipated from an overdose of these potent opioids.
Background
Dried blood spots (DBS) have many advantages over traditional clinical sample formats 
including increased analyte stability, small sample volume (<20 μL), decreased infection 
hazard for those handling samples, and reduced cost for shipping and storing. Used 
extensively for neonatal screening since the 1960s,1 improvements in analytical 
instrumentation sensitivity has made DBS a convenient biological matrix for pharmaceutical 
studies and exposure analyses.2–4
Traditional preparation of DBS often requires a manually intensive process of punching, 
extracting each punch individually, concentrating, and reconstituting prior to analysis of 
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each spot. Automation of extraction processes minimizes the number of manual steps, 
reducing potential errors. Recent technologies for automating the extraction and/or mass 
spectrometric detection of DBS include paper spray,5 thin-layer chromatography,6,7 liquid-
surface analysis,8 and on-line DBS sample extraction with and without additional clean-
up.9–18 Flow-through extraction of DBS coupled to on-line SPE has also been developed;19 
this system performs an automated desorption of DBS, complete with the addition of 
internal standard, followed by online SPE with subsequent analysis by a mass spectrometer. 
Incorporation of a large size (6-mm) clamp accommodates desorption of an entire small 
volume (~5 μL) DBS, minimizing quantitation challenges resulting from spot spread caused 
by hematocrit variations among blood samples.16,20,21 Additionally, the option for heated 
desorption solvent, has shown improvements to variations in extraction due to 
hematocrit.20,22,23 The automated desorption of DBS has been applied to multiple analytes 
with mass spectrometric analysis.15,17,20,24,25 More specifically, fentanyl has been 
quantitated from DBS using automated desorption but required separate SPE and LC 
separation.25 Fentanyl and two analogs have also been detected from DBS using manual 
extraction with HPLC-MS/MS.26,27
Fentanyl, initially synthesized by Janssen Pharmaceuticals in the 1960s, was the first in a 
class of potent opioid analgesics developed for chronic pain treatment, palliative care, and 
use as an anesthetic. Multiple analogs of fentanyl have been developed with varying 
potencies for use in the medical and veterinary fields.28 Analogs with no approved medical 
use have also been synthesized and are restricted as Schedule I compounds by the US Drug 
Enforcement Agency (DEA).29 As a strong opioid, fentanyl and its derivatives are frequently 
misused, resulting in overdoses and deaths.28 The drug poisoning rate involving opioid 
analgesics has approximately quadrupled from 1999 to 2013 with over 16,000 opioid-related 
deaths occurring in 2013.31 Fentanyl analogs have reportedly been misused in the US and 
Europe,30, 32–34 and as a result these compounds are an increasing public health concern.
Fentanyl exposures are confirmed through the analysis of clinical samples.35–41 Following 
overdose, the unaltered drug has been detected at concentrations ranging from 1.4–383 
ng/mL in whole blood.35,36,37,38,40 Although metabolites may also be present, they are 
detected at lower levels in blood than the unaltered drug; the use of other pharmaceuticals 
may further reduce the measured amount of metabolites.39
This paper describes the development and validation of an automated method for the 
quantitation of seven fentanyl analogs in DBS using flow through desorption coupled to on-
line solid phase extraction tandem mass spectrometry. The reported method incorporates 
isotopically labeled internal standards for four of the seven analogs. To our knowledge, no 
method has been developed for the analysis of multiple fentanyl analogs using automated 
DBS extraction. This work is critical for addressing the public health concern created by the 
misuse of these compounds.
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Experimental
Appropriate safety control measures (including engineering, administrative, and personal 
protective equipment) were used for all procedures based on a site-specific risk assessment 
that identified physical, health, and procedural hazards.
Chemicals, standards, and reagents
Fentanyl and 2H5-fentanyl were purchased from Cerilliant (Round Rock, TX). Carfentanil, 
sufentanil, and their corresponding N-phenyl-2H5 labeled forms, as well as 13C6-alfentanil 
HCl were custom synthesized by Battelle (Columbus, OH). Lofentanil, alfentanil, 3-methyl 
fentanyl, and α-methyl fentanyl, were generous gifts from a variety of sources listed in the 
Acknowledgements. Structures of all target analytes are shown in Figure 1. High-
performance liquid chromatography (HPLC)-grade methanol and acetonitrile were 
purchased from Tedia Company, Inc. (Fairfield, OH). Formic acid (99%) and ammonium 
hydroxide (28.6%) were purchased from Sigma Aldrich (Pittsburgh, PA). Deionized (DI) 
water (>18MΩ·cm) was prepared on-site using an installed water purification system (Aqua 
Solutions, Inc., Jasper, GA). Pooled whole blood and a convenience set of individual whole 
blood samples were purchased from Tennessee Blood Services (Memphis, TN). Use of 
deidentified spiked blood from a commercial source was not deemed to constitute human 
subject research.
Stocks and working solutions
Individual stock solutions for each analyte were prepared at 10.0 μg/mL in DI water. From 
the stock solutions, a working solution containing all fentanyl analogs at 500 ng/mL was 
prepared volumetrically in DI water. This working solution was then diluted to create 
solution A at 50.0 ng/mL in DI water and solution B at 5.00 ng/mL. For internal standards, 
individual stock solutions were prepared at 100 μg/mL in DI water (2H5-fentanyl, 2H5-
carfentanil, and 2H5-sufentanil) and at 20.0 μg/mL in DI water (13C6-alfentanil HCl). These 
stocks were diluted to prepare a mixture of all labeled compounds at 25.0 ng/mL in DI 
water. All solutions were stored at −20°C.
Materials preparation
Calibrators were prepared volumetrically in pooled whole human blood using the working 
solutions to achieve final concentrations of 1.00, 10.0, 25.0, 50.0, and 100 ng/mL. Two 
quality control standards (QCs) were prepared in the same manner as the calibrators at low 
(QL) and high (QH) concentrations of 7.50 and 75.0 ng/mL, respectively, also in pooled 
whole blood. All calibrators, QC samples, and individual blood samples were spotted at 5.00 
μL onto FTA DMPK-C blood spot cards (GE LifeSciences, Pittsburgh, PA). The cards were 
allowed to dry at ambient temperature for a minimum of two hours before analysis or 
storage with desiccant at −20°C.
Instrumentation
Flow-through extraction of all dried blood spots was performed using a prototype device 
from Spark Holland (Emmen, Netherlands) consisting of an automated cartridge exchanger 
(ACE), a high pressure dispensing pump (HPD) for solvent delivery, two high performance 
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liquid chromatography (HPLC) pumps, and a DBS card autosampler (DBSA) with 6-mm 
clamp head and 20 μL sample loop for internal standard addition. Analytes were detected 
using an AB Sciex 6500 Triple Quadrupole Mass Spectrometer (MS) (Foster City, CA). 
Individual whole blood samples were centrifuged in a capillary tube at 12000 rpm using a 
M24 Hematocrit Centrifuge (LW Scientific, Lawrenceville, GA) for measurement of 
hematocrit using a Micro-Capillary Reader (Damon/IEC Division, Needham Heights, 
MA).20
On-line DBS sample preparation, extraction procedure, and analysis
Analytes were desorbed using 1.2 mL of heated (100°C) 15:85 methanol: aqueous 1% 
formic acid. Internal standard was added using a 20 μL sample loop with the desorption 
solution prior to contact with the DBS. Analytes and internal standard were then trapped on 
a HySphereTM C18 HD SPE cartridge (7 μM, 10 × 2.0 mm ID) (Spark Holland, Emmen, 
Netherlands) which was preconditioned with 1 mL of methanol and equilibrated with 1 mL 
of aqueous 1% formic acid. The analytes were eluted off the SPE cartridge directly onto the 
mass spectrometer with a 3 minute gradient of 100% aqueous 1% formic acid to 100% 
acetonitrile at a flow rate of 0.5 mL/min. Each SPE cartridge was only used once.
Analytes were measured using TuboIonSpray® MS/MS in positive ion mode. Two 
transitions were monitored for each analyte and one transition was monitored for each 
internal standard, shown in supplemental table 1. Analyte-specific MS parameters were 
optimized for highest signal. Additional parameters used during analysis include the 
following values: curtain gas (CUR), 40 psi; nebulizer gas (GS1), 40 psi; turbo gas (GS2), 
40 psi; turbo gas temperature (TEM), 550°C with the interface heater (IHE) on; collision gas 
(CAD), 7 producing a pressure reading of nitrogen @ 2.0 × 10–5 Torr; ionspray potential 
(IS), 4200 V; and entrance potential (EP), 10 V.
Data Processing
Data analysis was performed using Analyst software (Sciex, Version 1.5.1). Linear 
regression analysis of the calibrator concentration versus the ratio of the quantification ion 
area to the internal standard ion area with 1/x weighting was used for quantitation. 
Isotopically-labeled analytes were used as internal standards for corresponding unlabeled 
analogs. Isotopically-labeled carfentanil was also used as internal standard for lofentanil, α-
methyl fentanyl, and 3-methyl fentanyl due to similar structure and retention time. All 
calibration curves meeting the correlation coefficient requirement of 0.980 or greater were 
accepted for use.
Method Characterization
Data from 20 replicate calibration curves and QC samples were evaluated to assess accuracy 
and precision over 8 weeks with two analysts running a maximum of two curves per day. 
Potential matrix interferences (selectivity) were evaluated by analyzing 20 unidentified 
patient samples from individuals with no anticipated exposure to fentanyls. Ten individual 
whole blood samples were also fortified at 6.0 and 30 ng/mL, five at each spiking level. 
Each individual blood sample was analyzed in triplicate.
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Matrix Effects
Matrix effects were evaluated by adding the analyte mixtures (solution A and solution B) to 
the desorption solvent using the internal standard sample loop described above. Both 
solutions were passed through a blank card as well as DBS from two different blood pools. 
Area counts were used to calculate matrix effects for each compound using the following 
equation:
Matrix Effects (%) = ((Response with blank card matrix -Response with DBS matrix)/
(Response with blank card matrix))×100%
Limit of Detection
The limit of detection (LOD) was determined from the 20 replicate results obtained for the 
four lowest calibrators. The deviation of the blank (S0) for each analyte in this method was 
extrapolated from the plot of the standard deviations of the lowest four calibrators versus 
their respective concentrations. S0, the y-intercept of the linear regression analysis of these 
data points, was multiplied by three to determine the LOD.41 These results were confirmed 
by the analysis of low level spikes at the estimated LOD values made in the same manner as 
the calibrators and QCs.
Results and Discussion
Automated DBS extraction, online-SPE and MS conditions
Automated DBS extraction was applied to the analysis of multiple fentanyl analogs to 
promote the use of DBS as a sampling mechanism. This novel instrument design introduced 
internal standard to the sample during desorption of the analytes, reducing manual steps 
required for analysis and possibly enabling field collection of DBS. Initial mass 
spectrometric parameters were determined by individually infusing each compound into the 
electrospray source and optimizing for highest response. Two mass spectrometric transitions 
were selected per compound to achieve maximum sensitivity and minimal matrix 
interferences.
Multiple online-SPE cartridges were investigated for compatibility with the automated DBS 
desorption. These sorbents included Oasis® HLB (Waters, Milford, MA), which was 
previously used for these compounds41 Resin SH, C2-SE, CN-SE, C8-SE, C18 HD, Resin 
GP, MM anion, and MM cation (HySphere™) (Spark, Emmen, Netherlands). The C18 HD 
cartridge, which has been used previously with this system for similar compounds25 gave the 
highest response with baseline resolution from matrix peaks for all analytes, and thus was 
selected for further development.
Desorption of fentanyl analogs from the DBS was optimized for several solvent conditions 
including composition, volume, temperature, and dispensing speed. To ensure retention of 
the analytes on reverse phase SPE, water was initially used for desorption. Formic acid was 
added to release any analogs potentially bound to proteins in the DBS;43 the analytes were 
found to be poorly desorbed with this solution. Given the high solubility of fentanyl in 
methanol, the addition of methanol to the desorption solvent was investigated to improve 
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recovery. A mixture of 85% aqueous 1% formic acid and 15% methanol was selected to 
maximize desorption while maintaining sufficient water content to also maximize retention 
on the SPE cartridge for all analytes. Solvent extraction volume was evaluated from 0.50 to 
1.5 mL; an increase in response for all analytes was seen until 1.2 mL, so this volume was 
selected. The desorption solvent temperature was tested at 50°C, 75°C, 100°C, and at 
ambient temperature (~25°C). A slight increase in response was seen as temperatures 
increased, so 100°C was chosen as the optimal temperature. This higher solvent temperature 
may overcome extraction challenges resulting from hematocrit variations.20 Dispensing 
speed of the solvent did not impact desorption; therefore, a nominal value of 2000 μL/min 
was used.
Elution from the online SPE cartridge was evaluated using both methanol and acetonitrile. 
Acetonitrile was selected as the strong elution solvent and resulted in improved peak shape 
and rapid elution of all compounds (Figure 2). Baseline separation was not achieved for all 
compounds, of particularly concern, the constitutional isomers α-methyl fentanyl and 3-
methyl fentanyl were not separated under these conditions. To address this issue, unique 
quantitation transitions were selected for each compound to prevent signal contribution 
between all analytes, including the isomers as previously documented.42 Because baseline 
resolution from detectable matrix interferences was achieved with SPE alone, no additional 
separation was deemed necessary for this method.
Matrix effects
Matrix effects were investigated in two blood pools at two concentrations, 5.0 ng/mL and 50 
ng/mL and analysed in triplicate. Data shown in Table 1 is from one pool at a single 
concentration, as both blood pools gave comparable results. As shown in Table 1, the matrix 
effects were high (68–96%) for all analytes at the 50 ng/mL concentration; similar matrix 
effects were seen at the lower concentration ranging from 58–91%. These high matrix 
effects were not unexpected as the DBS was extracted with a significant aqueous content, 
solubilizing many components of the blood which can suppress signal. Comparable matrix 
effects have been noted in urine for reverse phase SPE followed by LC-MS/MS.42 
Additionally, an in-house evaluation of plasma using similar SPE-LC-MS/MS parameters42 
resulted in matrix effects ranging 19–93% for the same fentanyls and normetabolites. The 
combination of SPE and HPLC has not significantly decreased matrix effects for these 
analytes from clinical samples. For this study, further reduction of matrix effects was not 
expected with the addition of HPLC separation. The main concern with high matrix effects 
remains the loss of sensitivity; however, the limit of detection (Table 1) for each analyte was 
lower than values expected following overdose (1.4–383 ng/mL).35,36,37,38,40
Method Characterization
This analytical method was characterized by evaluating 20 sets of calibration curves and QC 
samples in matrix at concentrations of 7.5 ng/mL and 75 ng/mL. Calibrators in dried blood 
spots were extracted and analyzed with the QC samples over the course of two months by 
two analysts. Sensitivity, accuracy, and precision were calculated based on the quantitation 
ion transition. The precision, defined by the %RSD, was <15% for analytes with matched 
isotopically labeled internal standards; for analytes without labeled internal standard, 
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precision ranged from 15–24% (Table 2). The accuracies for the QC samples and the lowest 
calibrator were within ±10% of the expected value for all analytes. For the four analytes 
with matched internal standards, accuracy and precision were within the FDA guidelines for 
biomedical testing.44
Linearity of the calibrator curves was confirmed through the back calculation of the 
calibrators, which resulted in mean accuracies within 10% for all analytes. Corresponding 
RSDs from the 20 analytical runs was less than 16% for all analytes, with the exception of 
α- and 3-methyl fentanyl with variances up to 25%. All curves achieved a correlation 
coefficient of 0.980 or higher. To confirm the selection of regression weighting, the sum of 
residuals were compared between no weighting, 1/×, and 1/×2; 1/× weighting resulted in a 
lower sum of residuals than no weighting. Although 1/×2 weighting had a lower sum of 
residuals overall, the correlation coefficient did not meet the criteria; therefore, 1/× 
weighting was selected.
The linear range for this method was established to confirm overdose exposures to these 
fentanyls, with calibrators from 1.0–100 ng/mL. The calculated LODs ranged from 0.15–
0.66 ng/mL (Table 1); however, to ensure the confirmation ion was detected for all analytes, 
the lowest calibrator was set at 1.0 ng/mL (Figure 2 and Supplementary Figure 1). It should 
also be noted that sensitivity was greatly impacted by the small sample volume used in this 
method. While past urinary methods had a lower limit of quantitation of 0.050 ng/mL, these 
methods required a 100-fold increase in sample volume (500 μL) plus a concentration 
step.42 For a 1.0 ng/mL sample the DBS method evaluated here injected 0.005 ng on 
cartridge, whereas 0.1 ng were injected on column for the urinary SPE-LC-MS/MS method. 
This significant difference confirms that sample volume plays a critical role in sensitivity 
and is the most limiting factor for this DBS method.
Carry-over between samples was also investigated, as this was identified as a concern in a 
previous study with this instrument.25 A blank DBS sample was evaluated following the 
highest calibrator on every run. There were no detectable responses in this blank sample, 
confirming that carry-over using a 5 μL spot was not an issue for this method.
A convenience set of twenty individual blood samples with no known exposure to these 
compounds were analyzed to measure any endogenous interferences. No interferences were 
observed at the anticipated retention time for either the quantitation or confirmation 
transition for any of the fentanyl analytes. These results indicated that this method is 
selective for fentanyl analogs and should not result in false positives.
Individual blood samples fortified at 6.0 ng/mL and 30 ng/mL were evaluated for accuracy 
and precision (N=3). The hematocrit of these samples was measured and ranged from 34.8% 
to 48.0% which is in the normal range for healthy adults. The 30 ng/mL spike level 
demonstrated high precision and accuracy for fentanyl, sufentanil, carfentanil, lofentanil, 
and alfentanil; however, α-methyl fentanyl and 3-methyl fentanyl showed more variability 
(Figure 3). Similar results were observed for all analytes for the 6.0 ng/mL spike level with 
the exception of alfentanil, which was biased low at this concentration. Although hematocrit 
has been documented to negatively impact quantitation from DBS,21–23,45,46 no trends 
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associated between concentration and hematocrit level was observed, therefore, no 
correlation was identified.
Conclusions
An automated method for desorption, extraction, and detection of seven fentanyl analogs 
from DBS has been developed and validated. Accuracy values for all analytes and precision 
for analytes with matching isotope enriched internal standards, except for alfentanil at 6.00 
ng/mL, were within the FDA specifications for bioanalytical methods.43 Thus this method 
can be used to quantitate four fentanyl analogs. With a reportable range of 1.0–100 ng/mL, 
concentrations measured in blood products from overdose cases can be detected.33–36,38 
Although, additional evaluation of clinical samples could necessitate a lower limit of 
detection as the potency for these analogs can vary greatly. Analysis of simulated clinical 
samples confirmed the ability of this method to positively identify fentanyl analogs in 
individual samples. Use of automated preparation with online SPE amenable to DBS 
samples provided a streamlined laboratory workflow and minimized analyst exposure to 
potentially hazardous substances while maximizing sample throughput. Future work should 
include analysis of clinical samples to determine the clinical relevant range for all analytes 
and investigation of samples with hematocrit outside the normal range.
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Figure 1. 
Structures of fentanyl analogs with * indicating isotopically labeled internal standard. 
Analogs with out matched internal standard used carfentanil as a suragate internal standard.
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Figure 2. 
SPE-MS/MS chromatogram of fentanyl analogs eluted from 5 μL dried blood spots. 
Extracted ion chromatograms of (A) all analytes at a concentration of 7.5 ng/mL in pooled 
whole blood and of (B) sufentanil at a concentration of 1.0 ng/mL.
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Figure 3. 
Analysis of individual blood samples (A) five fortified at 6.0 ng/mL and (B) five fortified at 
30 ng/mL, N=3. The dotted lines represent 15% precision from spiked value.
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Table 1
Matrix effects in % and limit of detection (LOD). Matrix effects were calculated at a concentration of 50 
ng/mL (N=3).
Analyte Matrix Effects (%) Calculated LOD (ng/mL)
Fentanyl 80 ± 4 0.16
Sufentanil 96 ± 1 0.24
Carfentanil 83 ± 4 0.25
Alfentanil 92 ± 1 0.15
Lofentanil 68 ± 3 0.35
α-methyl fentanil 83 ± 4 0.66
3-methyl fentanil 88 ± 3 0.56
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